Xilio therapeutics reports pipeline and business highlights and first quarter 2022 financial results

Clinical programs for xtx202, a tumor-selective il-2, and xtx101, a tumor-selective anti-ctla-4, continue to advance with preliminary data anticipated in 2022

XLO Ratings Summary

XLO Quant Ranking